------------------------------
OMB APPROVAL
OMB Number: 3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response 10.4
------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
RIGEL PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK
--------------------------------------------------------------------------------
(Title of Class of Securities)
7665596034
--------------------------------------------------------------------------------
(CUSIP Number)
DECEMBER 31, 2006
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
------------------------ ------------------
CUSIP No. 7665596034 13G Page 2 of 8 Pages
------------------------ ------------------
1. NAMES OF REPORTING PERSONS
Great Point Partners, LLC
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
37-1475292
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
5. SOLE VOTING POWER
NUMBER OF SHARES
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY EACH 1,530,600
REPORTING PERSON 7. SOLE DISPOSITIVE POWER
WITH 8. SHARED DISPOSITIVE POWER
1,530,600
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,530,600
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.1%
12. TYPE OF REPORTING PERSON (See Instructions)
OO
------------------------ ------------------
CUSIP No. 7665596034 13G Page 3 of 8 Pages
------------------------ ------------------
1. NAMES OF REPORTING PERSONS
Dr. Jeffrey R. Jay, M.D.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
5. SOLE VOTING POWER
NUMBER OF SHARES
0
BENEFICIALLY
6. SHARED VOTING POWER
OWNED BY EACH
1,530,600
REPORTING PERSON
7. SOLE DISPOSITIVE POWER
WITH
0
8. SHARED DISPOSITIVE POWER
1,530,600
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,530,600
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.1%
12. TYPE OF REPORTING PERSON (See Instructions)
IN
------------------------ ------------------
CUSIP No. 7665596034 13G Page 4 of 8 Pages
------------------------ ------------------
ITEM 1.
(a) Name of Issuer
Rigel Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices
1180 Veterans Blvd.
South San Francisco, CA 94082
ITEM 2.
(a) Name of Person Filing
Great Point Partners, LLC
Dr. Jeffrey M. Jay, M.D.
The Reporting Persons have entered into a Joint Filing Agreement,
dated February 14, 2007, a copy of which is filed with this
Schedule 13G as Exhibit A, pursuant to which the Reporting Persons
have agreed to file this statement jointly in accordance with the
provisions of Rule 13d-1(k)(1) under the Act.
(b) Address of Principal Business Office, or if none, Residence
The address of the principal business office of each of the
Reporting Persons is
165 Mason Street, 3rd Floor
Greenwich, CT 06830
(c) Citizenship
Great Point Partners, LLC is a limited liability company organized
under the laws of the State of Delaware. Dr. Jeffrey M. Jay, M.D.
is a citizen of the United States.
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
76655903
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(b) OR
240.13D.2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable.
(a) [_] Broker or dealer registered under Section 15 of the Act
(15 U.S.C. 78o)
(b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C.
78c).
(c) [_] Insurance company as defined in Section 3(a)(19) of the
Act (15. U.S.C. 78c).
(d) [_] Investment Company registered under Section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [_] An investment adviser in accordance with
ss.240.13d-1(b)(1)(ii)(E).
------------------------ ------------------
CUSIP No. 7665596034 13G Page 5 of 8 Pages
------------------------ ------------------
(f) [_] An employee benefit plan or endowment fund in accordance
with ss.240.13d-1(b)(1)(ii)(F).
(g) [_] A parent holding company or control person in accordance
with ss.240.13d-1(b)(1)(ii)(G).
(h) [_] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j) [_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
ITEM 4. OWNERSHIP
Great Point Partners, LLC ("Great Point") is the investment manager
of Biomedical Value Fund, L.P. ("BVF"), and by virtue of such
status may be deemed to be the beneficial owner of the 826,524
shares of Common Stock of the Issuer owned by BVF (the "BVF
Shares"). Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing
member of Great Point, has voting and investment power with respect
to the BVF Shares, and therefore may be deemed to be the beneficial
owner of the BVF Shares.
Great Point is the investment manager of Biomedical Offshore Value
Fund, Ltd. ("BOVF"), and by virtue of such status may be deemed to
be the beneficial owner of the 704,076 shares of Common Stock of
the Issuer owned by BOVF (the "BOVF Shares"). Dr. Jay, as senior
managing member of Great Point, has voting and investment power
with respect to the BOVF Shares, and therefore may be deemed to be
the beneficial owner of the BOVF Shares.
Great Point and Dr. Jay disclaim beneficial ownership of the BVF
Shares and the BOVF Shares, except to the extent of their
respective pecuniary interest.
Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified
in Item 1.
1. GREAT POINT PARTNERS, LLC
(a) Amount beneficially owned: 1,530,600
(b) Percent of class: 6.1%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: - 0 -
(ii) Shared power to vote or to direct the vote: 1,530,600
(iii) Sole power to dispose or to direct the disposition of:
- 0 -
(iv) Shared power to dispose or to direct the disposition
of: 1,530,600
------------------------ ------------------
CUSIP No. 7665596034 13G Page 6 of 8 Pages
------------------------ ------------------
2. DR. JEFFREY R. JAY, M.D.
(a) Amount beneficially owned: 1,530,600
(b) Percent of class: 6.1%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,530,600
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition
of: 1,530,600
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not Applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
See item 4.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable.
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as
participant in any transaction having that purpose or effect.
------------------------ ------------------
CUSIP No. 7665596034 13G Page 7 of 8 Pages
------------------------ ------------------
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: February 14, 2007
GREAT POINT PARTNERS, LLC
By: /s/ Dr. Jeffrey R. Jay, M.D.
----------------------------
Dr. Jeffrey R. Jay, M.D.,
as senior managing member
/s/ Dr. Jeffrey R. Jay, M.D.
----------------------------------
DR. JEFFREY R. JAY, M.D.
Exhibit A
---------
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G
The undersigned hereby agree as follows:
(i) Each of them is individually eligible to use the Schedule 13G to
which this Exhibit is attached, and such Schedule 13G is filed on behalf of each
of them; and
(ii) Each of them is responsible for the timely filing of such Schedule
13G and any amendments thereto, and for the completeness and accuracy of the
information concerning such person contained therein; but none of them is
responsible for the completeness or accuracy of the information concerning the
other persons making the filing, unless such person knows or has reason to
believe that such information is inaccurate.
Date: February 14, 2007
GREAT POINT PARTNERS, LLC
By: /s/ Dr. Jeffrey R. Jay, M.D.
----------------------------
Dr. Jeffrey R. Jay, M.D.,
as senior managing member
/s/ Dr. Jeffrey R. Jay, M.D.
----------------------------------
DR. JEFFREY R. JAY, M.D.